Tyrosine kinase inhibitorFDA-approvedAdjuvant
Tafinlar
Generic name: dabrafenib
How it works
Blocks the BRAF V600E mutation, a genetic abnormality that drives cancer cell growth.
Cancer types
Melanoma— BRAF V600E mutation
Lung Cancer— BRAF V600E-mutated
Efficacy
In clinical trials, around 40% of patients achieved an objective response, with a median recurrence-free survival of approximately 21.1 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Dabrafenib and Trametinib Before and After Surgery for Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Reduced-Dose Dabrafenib-Trametinib for Lung Cancer in Very Elderly Patient | Lung Cancer | observational | — | Source → |
| Treating Advanced Melanoma with Combination Therapies | Melanoma | phase-3 | — | Source → |
| Dabrafenib and Trametinib Rollover Study for Various Cancers | Lung Cancer | preclinical | — | Source → |
| Study Examines Treatment Options for Lung Cancer Patients with Specific Genetic Mutation | Lung Cancer | observational | Median progression-free survival was 7.5 months and median overall survival was 18.7 months in patients treated with dabrafenib and trametinib. | Source → |
| Comparing Treatments for Melanoma Patients | Melanoma | meta-analysis | Dabrafenib and trametinib improved recurrence-free survival (RFS) compared to anti-PD(L)1 therapies (hazard ratio [HR] 0.53, 95% CI, 0.40-0.70, P < .01). | Source → |
| Combining two cancer drugs may help overcome melanoma resistance | Melanoma | lab-study | — | Source → |
| Targeted Therapy Shows Promise in Treating Pediatric Melanoma | Melanoma | observational | — | Source → |
| Rare Eye Condition Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Rare Lung Cancer Patient Responds to Dabrafenib and Trametinib | Lung Cancer | observational | — | Source → |
| Neoadjuvant dabrafenib and trametinib for stage III melanoma: 5-year results | Melanoma | phase-2 | At 5 years, recurrence-free survival was 40% (95% CI 27% to 60%), distant metastasis-free survival was 57% (95% CI 42% to 76%), and overall survival was 80% (95% CI 67% to 94%). | Source → |
| Rare but Life-Threatening Side Effect of Melanoma Treatment | Melanoma | observational | — | Source → |
| Combining Medications for Advanced Melanoma Shows Promise | Melanoma | phase-2 | The confirmed objective response rate was 29.2%. | Source → |
| New Methods for Detecting Cancer Drug Dabrafenib | Lung Cancer | lab-study | — | Source → |
| Melanoma Drug Exposure Linked to Survival | Melanoma | observational | Median overall survival was significantly longer in patients with trametinib C ≥ 15.6 ng/mL (22.8 vs. 12.6 months, P = 0.003) | Source → |
| Combination Therapy for Metastatic Melanoma Shows Promise | Melanoma | observational | The patient experienced complete remission for 19 months. | Source → |
| New way to deliver cancer drugs to melanoma cells | Melanoma | lab-study | Both DAB- and VEM-loaded NMs elicited enhanced response with respect to free drug treatments in 4 different melanoma cell lines. | Source → |
| Melanoma Treatment Comparison Study | Melanoma | phase-3 | The 2-year overall survival for those starting on arm A was 71.8% (95% CI, 62.5 to 79.1), and arm B 51.5% (95% CI, 41.7 to 60.4). | Source → |
| Dabrafenib and Trametinib Combination Shows Promise in Lung Cancer Patients | Lung Cancer | observational | The median progression-free survival was 17.5 months and the median overall survival was 25.5 months. | Source → |
| Pembrolizumab and other drugs improve cancer outcomes in melanoma patients | Melanoma | phase-2 | Median progression-free survival was 16.9 months with the combination of pembrolizumab, dabrafenib, and trametinib, compared to 10.7 months with dabrafenib and trametinib alone. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.